erlotinib has been researched along with candesartan cilexetil in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (candesartan cilexetil) | Trials (candesartan cilexetil) | Recent Studies (post-2010) (candesartan cilexetil) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 628 | 151 | 133 |
| Protein | Taxonomy | erlotinib (IC50) | candesartan cilexetil (IC50) |
|---|---|---|---|
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.2 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 2.4547 | |
| DNA polymerase kappa | Homo sapiens (human) | 7.4 | |
| DNA polymerase iota | Homo sapiens (human) | 6.2 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 5 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.7244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
1 review(s) available for erlotinib and candesartan cilexetil
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |